Health Care·Biotechnology·$24.9B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $4.37 | N/A | +17.04% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $4.37 | N/A | +17.04% |
| Revenue | N/A | N/A | N/A |
Tone: Neutral
Management expressed a commitment to innovation and addressing market challenges. However, they did not provide updated guidance, leaving some uncertainty.
Management highlighted ongoing efforts in product development.
They acknowledged competitive pressures in the market.
No specific guidance was provided for future quarters.
United Therapeutics reported a strong EPS performance, exceeding expectations by over 17%. However, the stock fell nearly 5% in reaction, likely due to the absence of revenue figures and any forward guidance. Investors may be cautious given the lack of clarity on future performance and competitive pressures mentioned during the call.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
HALLIBURTON CO
Jul 24, 2017